Audentes Therapeutics (BOLD) Trading Up 3.6%

Audentes Therapeutics (NASDAQ:BOLD) shares were up 3.6% during mid-day trading on Thursday . The stock traded as high as $37.70 and last traded at $37.92. Approximately 374,451 shares were traded during trading, a decline of 16% from the average daily volume of 443,163 shares. The stock had previously closed at $36.59.

Several research analysts recently issued reports on BOLD shares. BidaskClub raised shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 20th. HC Wainwright started coverage on shares of Audentes Therapeutics in a research note on Wednesday, December 20th. They set a “buy” rating and a $37.00 target price on the stock. Wedbush increased their target price on shares of Audentes Therapeutics to $56.00 and gave the stock an “outperform” rating in a research note on Thursday, January 4th. William Blair reissued a “buy” rating on shares of Audentes Therapeutics in a research note on Friday, January 5th. Finally, BMO Capital Markets set a $44.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research note on Friday, January 5th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Audentes Therapeutics currently has an average rating of “Buy” and an average price target of $35.56.

How to Become a New Pot Stock Millionaire

The firm has a market capitalization of $1,341.91, a price-to-earnings ratio of -11.14 and a beta of 1.39.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. analysts forecast that Audentes Therapeutics will post -3.43 earnings per share for the current year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 48,000 shares of the company’s stock in a transaction on Monday, March 26th. The shares were sold at an average price of $28.89, for a total transaction of $1,386,720.00. Following the transaction, the director now owns 414,231 shares in the company, valued at $11,967,133.59. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Suyash Prasad sold 1,900 shares of the company’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $30.00, for a total transaction of $57,000.00. Following the transaction, the vice president now owns 1,900 shares in the company, valued at approximately $57,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,138,107 shares of company stock worth $39,502,022. Corporate insiders own 47.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in BOLD. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics in the third quarter valued at about $143,000. Teacher Retirement System of Texas purchased a new stake in shares of Audentes Therapeutics in the fourth quarter valued at about $208,000. MetLife Investment Advisors LLC purchased a new stake in shares of Audentes Therapeutics in the fourth quarter valued at about $248,000. Virtus Fund Advisers LLC purchased a new stake in shares of Audentes Therapeutics in the fourth quarter valued at about $372,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Audentes Therapeutics by 86.1% in the third quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 6,667 shares during the last quarter. Institutional investors own 66.96% of the company’s stock.

WARNING: “Audentes Therapeutics (BOLD) Trading Up 3.6%” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/14/audentes-therapeutics-bold-trading-up-3-6.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply